Rapid Adenovirus Testing Trends and Forecast 2022

Posted by sandeep gade on November 11th, 2022

The Rapid Adenovirus Testing Market is bound to witness stupendous growth going forward. With advancements in technology, healthcare organizations are into the development of a holistic strategy for building awareness regarding advanced healthcare infrastructure. eBooks and blog posts are also being used to increase the benevolence amongst patients. The healthcare vertical is expected to move in this direction shortly.

Adenovirus is associated with a variety of non-specific symptoms or clinical syndromes, it is difficult to diagnose based on clinical criteria alone. Diagnosis is most accurate when the infection shows symptoms of an outbreak or when the individual shows symptoms of a serious illness.

quantification of adenovirus DNA by particularly sensitive PCR techniques is expected to be useful for diagnosis and treatment monitoring of adenovirus infections, especially in immunocompromised patients. This, in turn, is expected to underpin the growth of the adenovirus diagnostic testing market during the forecast period.

Additionally, growth in research and development of technologies for use in the diagnosis of acute respiratory infections of viral etiology is expected to propel the growth of the market. For example, in 2014 DiaSorin launched its sixth LIAISON test for the qualitative detection of adenovirus in stool samples in markets outside the US and UK.

More recently, the virus has been diagnosed by cell culture as an adenovirus that replicates efficiently in cell culture. Detection and amplification of adenoviral DNA by various PCR methods is becoming the most widely accepted experimental step for detecting adenoviral infection.

The Europe Rapid adenovirus testing market is expected to grow at a profitable rate over the forecast period. This growth is owed to the presence of an increasing number of key players and the opportunistic approach to new investments in the field of Rapid adenovirus testing.QIAGEN’s NeuMo Dx ™ HAdV Quant Assay got CEIVD certificate on 9 July 2021 for automated testing for the detection of human adenovirus infection.

Manufacturers offer a variety of immunoassays for the detection of adenovirus antigens. The SD BIOLINE Rota / Adeno Ag test is one of the immunochromatographic analyzes provided by Abbott that qualitatively detects the presence of rotavirus or adenovirus antigens in human feces specimens.

In 2017, Abbott worked with UCSF (University of California, San Francisco) to detect new viruses and develop traits and diagnostic tools to resolve potential health threats caused by adenovirus. Herb and Marion Sandler’s seed funding to the collaboration supported development of the ViroChip. Supplier is also focused on improving the quality of analysis by performing surveillance projects in various hospitals, which in turn are expected to create profitable growth opportunities in this market.

For more info: https://www.persistencemarketresearch.com/checkout/32627